Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01920555 · ClinicalTrials.gov registry record · Phase 2
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
A Phase 2 study of Treatment-Resistant Depression, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 6
- Study locations
NCT01920555 is a Phase 2 study of Treatment-Resistant Depression that has completed, run by Massachusetts General Hospital. The registered enrollment target is 99 participants, below the 372-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (73% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT01920555, a Phase 2 study of Treatment-Resistant Depression, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Placebo Midazolam
Study Locations (6)
Texas
- University of Texas Southwestern - Dallas
- Baylor College of Medicine - Houston
California
- Stanford University - Palo Alto
Connecticut
- Yale University - New Haven
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Mount Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01920555
The ClinicalTrials.gov registry entry for NCT01920555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 372-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (73% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT01920555 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01920555 about?
NCT01920555 is a clinical study titled "Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)". This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
What is the current status of trial NCT01920555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2014-12. Estimated completion is 2017-02.
What conditions does trial NCT01920555 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT01920555?
The interventions under investigation include: Ketamine (DRUG), Placebo Midazolam (DRUG).
Who is sponsoring clinical trial NCT01920555?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01920555 being conducted?
This trial has 6 study locations across California, Connecticut, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
-
Psilocybin rTMS for Treatment Resistant Depression
RECRUITING · Phase 2
-
Antidepressant Effects of Nitrous Oxide
RECRUITING · Phase 2
-
Mindfulness Engaged Neurostimulation for Depression
RECRUITING · Phase 2
-
Neural and Antidepressant Effects of Propofol
ACTIVE NOT RECRUITING · Phase 2
-
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.